Mybl2 Gene as Prognostic Biomarker in Breast Cancer: A Systematic Review

Breast cancer is a relevant public health problem, either because of its high incidence or because of mortality rates. There are several forms of classification of the pathology, so that it is demonstrated, currently, the direct influence of genetic aspects on the clinic of affected patients. In this sense, new genetic biomarkers have been sought to directly impact the understanding of the disease, as well as having prognostic value, being the MYBL2 gene important in this context.

Aim: Thus, the present study aimed to identify and select evidence about the MYBL2 gene as a prognostic biomarker of the disease. Following PRISMA Statement 2020 guidelines, a systematic search was conducted in electronic databases such as PubMed and Science Direct to identify studies evaluating MYBL2 as a prognostic genetic biomarker in breast cancer. A narrative synthesis was used to analyze and synthesize findings, according to established inclusion and exclusion.

Criteria: There were 122 related publications, 12 of which were selected to be evaluated for eligibility in full text, so that 5 articles were selected for the qualitative synthesis of this study The findings demonstrate the role of MYBL2 as a potential prognostic biomarker for breast cancer, and overexpression of this gene is an indicator of worse prognosis. However, more clinical studies are needed, mainly to evaluate the MYBL2 gene exclusively and not only together with other potential biomarker genes.